EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Differential Expression of Matrix Metalloproteinase-2 Expression in Disseminated Tumor Cells and Micrometastasis in Bone Marrow of Patients with Nonmetastatic and Metastatic Prostate Cancer: Theoretical Considerations and Clinical Implications—An Immunocytochemical Study

Nigel P Murray, Eduardo Reyes, Pablo Tapia, Leonardo Badínez, Nelson Orellana

Bone Marrow Research · 2012

DOI: 10.1155/2012/259351 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bone Marrow Research, 2012. Verfasst von Nigel P Murray und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Division of Medicine, Hospital de Carabineros de Chile, Simón Bolívar 2200, Ñuñoa, 7770199 Santiago, Chile ; Instituto de Bio-Oncología, …. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Teaching Council, Hospital de Carabineros de Chile, Santiago.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Matrix metalloproteinase-2 (MMP-2) is important in the dissemination and invasion of tumor cells and activates angiogenesis. We present an immunocytochemical study of MMP-2 expression in circulating prostate cells (CPCs), disseminated tumor cells (DTCs), and micrometastasis (mM) in bone marrow of men with prostate cancer. Methods and Patients . Tumor cells were identified with anti-PSA immunocytochemistry. Positive samples underwent processing with anti-MMP-2, its expression was compared with Gleason score, concordance of expression, and metastatic and nonmetastatic disease.

Results

215 men participated, CPCs were detected in 62.7%, DTCs in 62.2%, and mM in 71.4% in nonmetastatic cancer; in metastatic cancer all had CPCs, DTCs, and mM detected. All CPCs and DTCs expressed MMP-2; in mM MMP-2 expression was positively associated with increasing Gleason score. MMP-2 expression in CPCs and DTCs showed concordance. In low grade tumors, mM and surrounding stromal cells were MMP-2 negative, with variable expression in high grade tumors; in metastatic disease, both mM and stromal cells were MMP-2 positive.

Conclusions

CPCs and DTCs are different from mM, with inhibition of MMP-2 expression in mM of low grade tumors. With disease progression, MMP-2 expression increases in both mM and surrounding stromal cells, with implications for the use of bisphosphonates or MMP-2 inhibitors.

Autor:innen und Institutionen

  • Hematology, Division of Medicine, Hospital de Carabineros de Chile, Simón Bolívar 2200, Ñuñoa, 7770199 Santiago, Chile ; Instituto de Bio-Oncología, Avenida Salvador 95, Oficina 95, Providencia, 7500710 Santiago, Chile…

Förderung

  • Teaching Council, Hospital de Carabineros de Chile, Santiago

Zitieren

APA

Murray, N. P., Reyes, E., Tapia, P., Badínez, L., & Orellana, N. (2012). Differential Expression of Matrix Metalloproteinase-2 Expression in Disseminated Tumor Cells and Micrometastasis in Bone Marrow of Patients with Nonmetastatic and Metastatic Prostate Cancer: Theoretical Considerations and Clinical Implications—An Immunocytochemical Study. Bone Marrow Research. https://doi.org/10.1155/2012/259351

Vancouver

Murray NP, Reyes E, Tapia P, Badínez L, Orellana N. Differential Expression of Matrix Metalloproteinase-2 Expression in Disseminated Tumor Cells and Micrometastasis in Bone Marrow of Patients with Nonmetastatic and Metastatic Prostate Cancer: Theoretical Considerations and Clinical Implications—An Immunocytochemical Study. Bone Marrow Research. 2012. doi:10.1155/2012/259351

BibTeX
@article{Murray2012,
  author = {Murray, Nigel P and Reyes, Eduardo and Tapia, Pablo and Badínez, Leonardo and Orellana, Nelson},
  title = {Differential Expression of Matrix Metalloproteinase-2 Expression in Disseminated Tumor Cells and Micrometastasis in Bone Marrow of Patients with Nonmetastatic and Metastatic Prostate Cancer: Theoretical Considerations and Clinical Implications—An Immunocytochemical Study},
  journal = {Bone Marrow Research},
  year = {2012},
  doi = {10.1155/2012/259351}
}
Kostenlos starten →